Raymond James Financial’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Raymond James Financial's CRL Position: Q3 2026 in Review
Raymond James Financial reduced its Charles River Laboratories (CRL) stake by 12% in Q3 2026, selling an estimated $8.43M and leaving 224,790 shares worth $66.3M. The position accounts for 0.02% of the portfolio, ranked #770.
Raymond James Financial first reported a position in CRL in Q4 2024 and has held it in 8 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Raymond James Financial held 224,790 shares of Charles River Laboratories worth $66.3M as of Q3 2026.
- Raymond James Financial sold 31,989 Charles River Laboratories shares in Q3 2026, an estimated $8.43M.
- Charles River Laboratories made up 0.02% of Raymond James Financial's portfolio in Q3 2026, its #770 holding.
- Raymond James Financial first reported a position in Charles River Laboratories in Q4 2024 and has held it in 8 quarters since.
- 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.